ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2012
Factors associated with receipt of breast cancer adjuvant chemotherapy in a diverse population-based sample.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis.Breast cancer research and treatment · 2013Pooled it
- Adjuvant Chemotherapy Outcomes in Older Adults With Nonmetastatic Triple-Negative Breast Cancer.JAMA network open · 2026Article
- Prevalence and predictive testing preferences for breast cancer treatment side effects.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- The influence of socio-economic status on the fulfilment of Saint-Gallen recommendations for early-stage breast cancer.Scientific reports · 2025Article
- Anatomy Versus Biology: What Guides Chemotherapy Decisions in Older Patients With Breast Cancer?The Journal of surgical research · 2024Article
- Patterns of chemotherapy receipt among patients with hormone receptor-positive, HER2-negative breast cancer.Breast cancer research and treatment · 2024Article
- Benefit of adjuvant chemotherapy in lymph node-negative, T1b and T1c triple-negative breast cancer.Breast cancer research and treatment · 2024Article
- Survival Benefit of Chemotherapy According to 21-Gene Recurrence Score in Young Women with Breast Cancer.Annals of surgical oncology · 2023Article
- Utility of linking survey and registry data to evaluate interventions and policies to address disparities in breast cancer survivorship among young women.Evaluation and program planning · 2021Article
- Determinants of Guideline-Discordant Breast Cancer Care.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2021Article
- Symptom Experience, Management, and Outcomes According to Race and Social Determinants Including Genomics, Epigenomics, and Metabolomics (SEMOARS + GEM): an Explanatory Model for Breast Cancer Treatment Disparity.Journal of cancer education : the official journal of the American Association for Cancer Education · 2020Article
- Cross-Canada differences in early-stage breast cancer treatment and acute-care use.Current oncology (Toronto, Ont.) · 2019Article
- Demographic, clinical, and geographical factors associated with lack of receipt of physician recommended chemotherapy in women with breast cancer in Texas.Cancer causes & control : CCC · 2019Article
- Racial/ethnic differences in the utilization of chemotherapy among stage I-III breast cancer patients, stratified by subtype: Findings from ten National Program of Cancer Registries states.Cancer epidemiology · 2019Article
- A Nomogram To Predict The Overall Survival Of Breast Cancer Patients And Guide The Postoperative Adjuvant Chemotherapy In China.Cancer management and research · 2019Article
- Spotlight on the utility of the Oncotype DXInternational journal of women's health · 2018Review
- Annual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival.Journal of the National Cancer Institute · 2017Article
- Article
- Breast Cancer Disparities at Home and Abroad: A Review of the Challenges and Opportunities for System-Level Change.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Article
- Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2017Article
Corrections and comments
- Commented on by
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
purposeDisparities in receipt of adjuvant chemotherapy may contribute to higher breast cancer fatality rates among black and Hispanic women compared with non-Hispanic whites. We investigated factors associated with receipt of chemotherapy in a diverse population-based sample. PATIENTS AND
methodsWomen diagnosed with breast cancer between August 2005 and May 2007 (N = 3,252) and reported to the Detroit, Michigan, or Los Angeles County Surveillance, Epidemiology, and End Results (SEER) registry were recruited to complete a survey. Multivariable analyses examined factors associated with chemotherapy receipt.
resultsThe survey was sent to 3,133 patients; 2,290 completed a survey (73.1%), and 1,403 of these patients were included in the analytic sample. In multivariable models, disease characteristics were significantly associated with the likelihood of receiving chemotherapy. Low-acculturated Hispanics were more likely to receive chemotherapy than non-Hispanic whites (odds ratio [OR], 2.00; 95% CI, 1.31 to 3.04), as were high-acculturated Hispanics (OR, 1.43; 95% CI, 1.03 to 1.98). Black women were less likely to receive chemotherapy than non-Hispanic whites, but the difference was not significant (OR, 0.83; 95% CI, 0.64 to 1.08). Increasing age (even in women age < 50 years) and Medicaid insurance were associated with lower rates of chemotherapy receipt.
conclusionIn this population-based sample, disease characteristics were strongly associated with receipt of chemotherapy, indicating that clinical benefit guides most treatment decisions. We found no compelling evidence that black women and Hispanics receive chemotherapy at lower rates. Interventions that address chemotherapy use rates according to age and insurance status may improve quality of systemic treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.